Market Intelligence, Clinical Progress, and High-Purity Reagents for Microtubule Dynamics Modulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for STMN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | STMN1 Full-Length Recombinant Protein Human, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View STMN1 Products |
| Antigen (Mutants) | STMN1 Phosphomimetic/Null Mutants (S16D, S16A, S25D, S38D, S63A) For functional phosphorylation studies. Mass Spec Verified. |
View STMN1 Products |
| Gene Delivery | STMN1 Lentivirus Premade Particles Full-length ORF or shRNA for stable cell line construction. High Titer (>10^8 TU/ml). |
View STMN1 Products |
| Detection Ab | Anti-STMN1 Recombinant Rabbit mAb (High-Affinity Clone) For Western Blot, IP, and IHC validation. |
View STMN1 Products |
| Validator | STMN1 siRNA Set (3 unique targets) For knockdown verification and rescue experiments. |
View STMN1 Products |
| Binding Partner | TUBB (Tubulin Beta) Direct physical interaction partner for co-sedimentation assays. |
View TUBB Products |
| Pathway Regulator | YWHAZ (14-3-3 Zeta) Phospho-specific binding protein (Ser16/25/38). |
View YWHAZ Products |
| Functional Antagonist | TPX2 (Targeting Protein for Xklp2) Microtubule nucleation factor, spindle assembly synergy. |
View TPX2 Products |
| Related Target A | STMN2 (Stathmin 2 / SCG10) Neural-enriched homolog for family selectivity counter-screening. |
View STMN2 Products |
| Related Target B | TUBB3 (Tubulin Beta 3 Class III) Direct STMN1 binding partner, highly expressed in taxane-resistant tumors. |
View TUBB3 Products |
| Related Target C | AURKA (Aurora Kinase A) Kinase regulator in mitotic progression and synergistic oncology target. |
View AURKA Products |
Critical Assay Requirements
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phosphoregulation Complexity (Activity controlled by PKA/GSK3β phosphorylation at Ser16/25/38/63) | Phosphomimetic (S16D, S25D) and Phospho-null (S16A) Mutants available; Site-specific verification by Mass Spec |
| Tubulin Binding Affinity Quantification (Competition with endogenous tubulin) | High-purity (>95%) Monomeric STMN1 and TUBB proteins; Validated for Co-sedimentation & FP assays |
| Intracellular Target Engagement (CNS/Penetration validation) | Lentivirus-based Stable Cell Lines for Cellular Thermal Shift Assay (CETSA) and Rescue experiments |
| Off-target Microtubule Interference | TPX2/TUBB Ortholog Panel (Human/Mouse/Rat) for selectivity screening |
| Stathmin family cross-reactivity (STMN2/3/4) | Ortholog and family homolog proteins available; Sequence Verified by mass spec for strict counter-screening. |
| Taxane resistance mutation mapping | Drug-resistant mutant variants available upon custom request; theoretical MW confirmed by SDS-PAGE. |
Live STMN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (STMN1 Biomarker/Inhibitor)
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for STMN1-targeted therapeutics is shifting from indirect modulation (via tubulin-binding agents) to direct intracellular inhibition. As STMN1 overexpression emerges as a dominant mechanism of resistance to taxanes and vinca alkaloids, pharmaceutical programs are intensifying focus on combination regimens and novel modalities including PROTACs and peptide-based disruptors. The next wave of R&D is targeting phospho-specific protein-protein interactions (PPI) and allosteric sites distinct from the tubulin-binding groove, requiring sophisticated biochemical tools that distinguish between phospho-isoforms. No single commercial entity currently dominates the clinical landscape, leaving significant white-space opportunity for platform developers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic consortia, Emerging biotech | Solid Tumors (Taxane-resistant) | Tubulin Competition Assay (Need pure STMN1 + TUBB) |
| PROTACs/Degraders | Preclinical stage | Leukemia, Lung Cancer | Cellular Degradation Assay (Need high-titer Lentivirus) |
| siRNA/ASO | Silence Therapeutics, Alnylam (early) | Liver Metastases | Knockdown Efficiency Validation (Need validated siRNA) |
| Peptide Inhibitors | Academic groups | Brain Tumors (CNS penetration) | PPI Disruption (SPR/BLI with 14-3-3 proteins) |
| Biomarker Diagnostics | Diagnostics Firms | Prostate / Lung Cancer | Standardized Controls (Need Sequence-verified Recombinant Proteins) |